Proposed Section Structure
1. Highlights. 2. Clinical background and unmet need in heterozygous familial hypercholesterolemia. 3. Study design and methods. 4. Main efficacy results. 5. Genotype-specific response and mechanistic interpretation. 6. Clinical implications for lipid practice. 7. Strengths and limitations. 8. Conclusion. 9. Funding, registration, and citation.
Highlights
Lerodalcibep 300 mg given monthly was associated with a sustained approximately 50% reduction in LDL-C at both 48 and 72 weeks in patients with heterozygous familial hypercholesterolemia.
LDL-C lowering appeared independent of the residual functional activity of the pathogenic LDLR variant, addressing a long-standing mechanistic and therapeutic question in familial hypercholesterolemia.
More than 70% of participants achieved both at least a 50% LDL-C reduction and their risk-based LDL-C target despite high baseline LDL-C levels on background lipid-lowering therapy.
The findings support the concept that PCSK9 inhibition in heterozygous familial hypercholesterolemia acts predominantly through upregulation of the unaffected wild-type LDL receptor allele.
Clinical Background
Heterozygous familial hypercholesterolemia (HeFH) is one of the most common inherited metabolic disorders and remains a major driver of premature atherosclerotic cardiovascular disease (ASCVD). The disorder is characterized by lifelong elevation of LDL cholesterol caused most commonly by pathogenic variants in LDLR, and less often in APOB or PCSK9. Even with contemporary care, many patients do not achieve guideline-recommended LDL-C thresholds, particularly those with established ASCVD or those categorized as very high risk.
Statins remain the foundation of treatment, usually supplemented by ezetimibe. However, many HeFH patients have residual severe hypercholesterolemia despite combination therapy. PCSK9-directed treatment has therefore become central in intensive lipid management. Mechanistically, PCSK9 inhibition increases hepatic LDL receptor recycling and surface expression, thereby enhancing clearance of circulating LDL particles.
In HeFH, an important unresolved question has been whether the magnitude of LDL-C lowering with a PCSK9 inhibitor depends on the functional severity of the inherited LDLR defect. This matters clinically because physicians often infer that patients carrying “null” or severely defective LDLR variants may respond less well. While this intuition is biologically plausible, the heterozygous state means that the unaffected allele may still provide sufficient receptor reserve to permit a clinically meaningful response. Robust evidence in large genetically characterized cohorts has been limited.
The present nonrandomized clinical trial, published in JAMA Cardiology by Raal and colleagues, directly addresses that gap using a pooled phase 3 HeFH cohort treated with lerodalcibep, a plasma PCSK9 inhibitor.
Study Design and Methods
This report is a predefined pooled subanalysis from a worldwide open-label phase 3 extension program involving lerodalcibep. Participants had HeFH and required additional lipid-lowering therapy. They had previously been randomized within 5 phase 3 studies and then entered the open-label extension study conducted from December 2020 to May 2025. Data analysis occurred from March 2025 to February 2026.
All participants in the present analysis received lerodalcibep 300 mg subcutaneously once monthly for 72 weeks. The analysis was nonrandomized, and there was no concurrent control group in the extension phase. This is an important design feature when interpreting efficacy magnitude and especially when considering safety comparisons.
The co-primary efficacy endpoints were LDL-C reduction at weeks 48 and 72. Secondary and exploratory endpoints included LDL-C response according to familial hypercholesterolemia genotype and achievement of risk-based LDL-C goals recommended in current practice.
The study included 703 participants. Mean age was 53.8 years, with a range of 18 to 80 years; 372 participants, or 52.9%, were male. In the reported racial composition, 86 participants (12.2%) were Black, South Asian, or multiracial, and 617 (87.8%) were White. Most participants were at substantial cardiovascular risk: 217 participants (72.3%) had ASCVD or were at very high risk for ASCVD, while 195 (27.7%) were categorized as high risk. Although the percentages as presented in the abstract appear internally inconsistent with the total cohort size, these are reported here exactly as published in the provided text.
Background lipid-lowering therapy was intensive but still inadequate. Despite use of statins or ezetimibe in most participants, mean baseline LDL-C remained 144.9 mg/dL, with a large standard deviation of 61.9 mg/dL, underscoring the severity and heterogeneity of residual hypercholesterolemia in this population.
Genetic testing was available for 740 participants, representing 92.5% of those assessed in the larger pooled population from which the present cohort was derived. Monogenic FH-causing variants were identified in 455 participants (61.5%), and among these, 432 participants (95.7%) carried an LDLR pathogenic variant. The genotype-focused analysis therefore predominantly reflects LDLR-related HeFH, which is clinically appropriate because LDLR mutations account for the vast majority of molecularly confirmed cases.
Main Results
Magnitude and durability of LDL-C lowering
The central finding is the consistency of LDL-C reduction over time. Mean LDL-C fell by 50.3% at week 48 and by 50.3% again at week 72. The corresponding mean absolute LDL-C changes were -72.6 mg/dL at week 48 and -71.8 mg/dL at week 72. Standard deviations were substantial, around 28.8% for percentage change and about 49 to 51 mg/dL for absolute change, which is expected in a genetically diverse HeFH cohort treated on variable background regimens.
From a clinical standpoint, a 50% LDL-C reduction in HeFH is highly meaningful. For a patient beginning near the cohort mean baseline LDL-C of 145 mg/dL, such a reduction would bring LDL-C close to 72 mg/dL on average, though individual responses vary widely. This degree of lowering is consistent with the established efficacy range of currently available PCSK9-directed therapies and is particularly relevant in patients who remain above target despite maximally tolerated oral therapy.
Goal attainment
More than 70% of participants achieved both a reduction in LDL-C of at least 50% and their guideline-based LDL-C goal according to ASCVD risk category. This dual endpoint is more clinically useful than percentage reduction alone because it captures both intensity of response and practical target achievement. In real-world lipid clinics, clinicians frequently face patients who may achieve one but not the other: for example, a large percentage reduction without reaching goal because baseline LDL-C is very high, or goal attainment without a 50% reduction because baseline levels are modest. Achieving both in more than 70% of HeFH patients is a strong result.
Genotype and LDLR function
The most important scientific contribution of the study is the finding that LDL-C reduction with lerodalcibep was independent of LDLR variant functional activity. In other words, participants with different categories of LDLR pathogenic variants did not show materially different LDL-C responses based on the residual functional severity assigned to the variant.
This observation directly challenges a simplistic assumption that poorer LDLR function in the affected allele necessarily predicts a poorer response to PCSK9 inhibition in heterozygous disease. Instead, the data support a model in which the therapeutic effect is predominantly mediated by increased expression and recycling of the receptor encoded by the unaffected wild-type allele.
That mechanistic interpretation is biologically coherent. In HeFH, unlike homozygous familial hypercholesterolemia, there is typically one functioning LDLR allele. If PCSK9 inhibition stabilizes and recycles receptor protein from this normal allele, a robust increase in hepatocyte LDL uptake can still occur even when the mutant allele contributes little or no function. The present results therefore fit with the broader understanding that PCSK9 inhibitors are highly effective in most HeFH patients but considerably less effective in receptor-negative homozygous disease, where wild-type receptor reserve is absent.
Clinical Interpretation
For lipid specialists, general cardiologists, internists, and preventive clinicians, the practical message is straightforward: a pathogenic LDLR variant with low residual function should not be used as a reason to withhold or delay PCSK9 inhibition in HeFH. The trial suggests that genotype-defined LDLR functional severity is not a major determinant of treatment response in the heterozygous state.
This is especially relevant for patients with severe baseline hypercholesterolemia, established ASCVD, or repeated failure to meet targets despite statin-ezetimibe therapy. In such patients, therapeutic inertia often arises from uncertainty about expected benefit, access barriers, and assumptions that certain genetic subtypes may be “poor responders.” These data argue against such assumptions for most patients with HeFH.
The monthly dosing schedule is also clinically notable. Adherence is a recurrent challenge in chronic lipid management, particularly when polypharmacy is present. A once-monthly subcutaneous regimen may improve convenience for some patients compared with more frequent injection schedules, although the trial abstract does not provide adherence metrics or patient-reported treatment burden data.
Another strength is the high-risk composition of the cohort. The majority of participants had ASCVD or were at very high risk, making the findings highly relevant to the group in whom aggressive LDL-C lowering has the strongest evidence base for event reduction. While this trial was not designed to assess cardiovascular outcomes directly, the magnitude of LDL-C reduction is within the range typically associated with clinically important risk reduction when sustained over time.
Mechanistic Insight
The mechanistic conclusion proposed by the investigators deserves emphasis. They argue that LDL-C lowering in HeFH with PCSK9 inhibition is predominantly mediated by upregulation of the unaffected wild-type LDLR. This concept has several implications.
First, it reinforces the functional distinction between heterozygous and homozygous familial hypercholesterolemia. In HeFH, receptor reserve from one intact allele often remains therapeutically exploitable. In receptor-negative homozygous disease, by contrast, response to receptor-dependent therapies is markedly attenuated, which is why treatment often shifts toward receptor-independent strategies such as angiopoietin-like 3 inhibition, microsomal triglyceride transfer protein inhibition in selected contexts, or lipoprotein apheresis.
Second, the findings support integrating genotype into care for diagnostic certainty and cascade screening, but not necessarily for predicting response to PCSK9 inhibition in routine HeFH treatment decisions. Genotype remains important, but its role may be more in confirming diagnosis and family risk stratification than in selecting among receptor-based therapies within typical HeFH populations.
Third, the study may help refine counseling. Patients often ask whether having a “more severe mutation” means that advanced therapy will not work. These data permit a more reassuring and evidence-based answer in most heterozygous cases.
Strengths and Limitations
Strengths
The study has several important strengths. It includes a large HeFH cohort treated over a relatively long duration of 72 weeks, allowing assessment of response durability. Genetic testing was performed in a high proportion of participants, enabling a genotype-response analysis that has often been underpowered in prior work. The baseline LDL-C burden was substantial despite contemporary therapy, which makes the results relevant to real clinical practice. The predefinition of the pooled genotype subanalysis also strengthens interpretability.
Limitations
Several limitations should temper conclusions. Most importantly, this was a nonrandomized open-label extension analysis without a concurrent control group. Although LDL-C is an objective endpoint, open-label extension cohorts are inherently more vulnerable to selection effects, treatment persistence bias, and confounding by changes in background therapy.
The abstract does not provide confidence intervals, formal between-genotype comparison statistics, or detailed subgroup counts by specific functional classes of LDLR variants. Without those details, the precision of the “independent of LDLR function” conclusion cannot be fully appraised from the abstract alone.
Safety outcomes are not described in the provided abstract. For any long-term lipid-lowering therapy, tolerability, injection-site reactions, immunogenicity, discontinuation rates, and serious adverse events are clinically relevant. The absence of safety data in the summary does not imply an absence of safety issues; it simply limits what can be concluded here.
Generalizability also deserves consideration. The cohort was predominantly White, and while patients from other racial backgrounds were included, broader representation would improve confidence in applicability across diverse populations. In addition, the genotype findings are driven primarily by LDLR pathogenic variants, so extrapolation to APOB- or PCSK9-related HeFH should be cautious.
Finally, the trial evaluated lipid endpoints rather than hard cardiovascular outcomes. While LDL-C reduction is a validated surrogate and central treatment target in FH, definitive outcome studies remain the highest level of evidence for therapy positioning.
Relation to Current Guidelines and Existing Evidence
Current international and North American cholesterol guidelines consistently recommend intensive LDL-C lowering in familial hypercholesterolemia, especially in those with ASCVD or very high risk, using maximally tolerated statins followed by ezetimibe and then a PCSK9-targeted agent when goals are not met. The present trial aligns with that treatment framework and adds clinically useful granularity by showing that LDLR functional severity should not be overinterpreted as a barrier to efficacy in HeFH.
The results are also broadly concordant with prior experience using monoclonal antibody PCSK9 inhibitors, which have demonstrated substantial LDL-C reductions in HeFH across varied backgrounds. What distinguishes this report is the large genotype-informed dataset and the explicit mechanistic inference centered on the unaffected wild-type LDL receptor.
Conclusion
This pooled phase 3 nonrandomized analysis indicates that monthly lerodalcibep produces durable LDL-C reductions of about 50% in patients with heterozygous familial hypercholesterolemia who require additional lipid-lowering therapy. The most clinically important insight is that response appears independent of the functional activity of the pathogenic LDLR variant. For practice, that means clinicians should expect meaningful LDL-C lowering from PCSK9 inhibition across most HeFH genotypes and should prioritize treatment intensity based on absolute ASCVD risk and residual LDL-C burden rather than assumptions about variant severity alone.
Further reports with detailed subgroup statistics, full safety data, and ideally cardiovascular outcomes will help define the place of lerodalcibep among available PCSK9-targeted therapies. Even so, the current evidence strongly supports receptor-based PCSK9 inhibition as an effective strategy in HeFH, with the intact wild-type LDLR allele providing sufficient biological leverage for major LDL-C lowering in most patients.
Funding, Registration, and Citation
Trial registration: ClinicalTrials.gov Identifier NCT04798430.
Funding: Specific funding details were not provided in the supplied abstract text and should be confirmed from the full article.
Citation: Raal FJ, Fourie N, Scott R, Blom DJ, Basson MMV, Kayikcioglu M, Roth M, Vest J, Kallend D, Stein EA. Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. JAMA Cardiology. 2026-04-29. PMID: 42054033. URL: https://pubmed.ncbi.nlm.nih.gov/42054033
References
1. Raal FJ, Fourie N, Scott R, Blom DJ, Basson MMV, Kayikcioglu M, Roth M, Vest J, Kallend D, Stein EA. Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. JAMA Cardiology. 2026-04-29. PMID: 42054033.
2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188.
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285-e350.
4. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. European Heart Journal. 2013;34(45):3478-3490a.
